GlassScriptPhysician profile
Donald J Rose
NPI 1639193782
$1,773,258.37
in general payments reported to CMS, 2019-2025
8 companies · $3,322 in 2025
The $3,322 reported for 2025 was more than what 78% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356K · 2020: $331K · 2021: $371K · 2022: $366K · 2023: $342K · 2024: $4,494 · 2025: $3,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $349K · Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $349,421.60 |
| Food and Beverage | $652.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,742,250.78 | 2019-2024 | Arthrex |
| Smith+Nephew, INC. | $30,188.94 | 2019-2025 | Na |
| Suvon Surgical LLC | $170.05 | 2024 | |
| Stryker Corporation | $166.57 | 2021 | |
| Boston Scientific Corporation | $163.12 | 2023 | Wavewriter Alpha Prime 16 |
| Miach Orthopaedics, INC. | $161.34 | 2024 | |
| Lifenet Health | $102.57 | 2024 | Graftlink Ts, Quadlink |
| Brainlab, INC. | $55.00 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.